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ABSTRACT
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, 
no robust mechanisms exist to externally control the activity of T-cells at specific locations within the body. 
Such spatiotemporal control could help mitigate potential off-target toxicity due to incomplete molecular 
specificity in applications such as T-cell immunotherapy against solid tumors. Temperature is a versatile 
external control signal that can be delivered to target tissues in vivo using techniques such as focused 
ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate 
thermal actuation of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–
42ºC, and introduce genetic architectures enabling the tuning of the amplitude and duration of thermal 
activation. We demonstrate the use of these circuits to control the expression of chimeric antigen receptors 
and cytokines, and the killing of target tumor cells. This technology provides a critical tool to direct the 
activity of T-cells after they are deployed inside the body.
Keywords: T-cells, CAR, Thermal Control, Mammalian Synthetic Biology, Heat Shock Promoters, and 
Immunotherapy.
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Unlike small molecule and biologic therapies, cells have a natural ability to navigate, persist and proliferate 
within the body, providing the potential for more targeted and sustained disease treatment. This potential is 
enhanced by the capacity of cells to probe, process, and respond to their environment and carry out a wide 
range of sophisticated behaviors, which can be engineered using the tools of synthetic biology1. Among the 
cell types being developed for therapy, T-cells are one of the most promising due to their central roles in 
cancer, infectious disease and autoimmune disorders, along with their relative ease of isolation, genetic 
modification and re-engraftment. For example, this potential has been realized in T-cells engineered to 
express modularly targeted chimeric antigen receptors (CARs), allowing them to specifically eradicate 
cancers such as lymphomas bearing the CD19 antigen2,3,4,5. Unfortunately, it has been challenging to 
translate these successful results into solid tumors, where CAR T-cells encounter a more 
immunosuppressive environment6 and the risk of sometimes fatal on-target off-tumor toxicity due to the 
presence of tumor-overexpressed epitopes in healthy tissues7,8. Likewise, emerging approaches in which T-
cells are used to treat autoimmune disease through local immunosuppression carry the risk of reducing 
important immune system activity outside the target tissues9. Existing strategies seeking to reduce off-target 
toxicity use additional target recognition elements10,11 or chemically triggered kill switches12,13,14. However, it 
can be difficult to ensure perfect recognition solely through molecular markers, and premature termination 
of T-cell therapy using kill-switches turns off their beneficial therapeutic action.
Here we describe a cellular engineering approach to regulate the activity of therapeutic T-cells with 
greater specificity through a combination of molecular and physical actuation. This approach is designed to 
take advantage of the ability of technologies such as focused ultrasound (FUS) and magnetic hyperthermia 
to non-invasively deposit heat at precise locations in deep tissue15–18. By engineering thermal bioswitches 
that allow T-cells to sense small changes in temperature and use them as inputs for the actuation of genetic 
circuits, we enable these penetrant forms of energy to spatially control T-cell activity. Our approach is based 
on heat shock promoters (pHSP), which have been shown to drive gene expression in response to FUS-
delivered heating19–21, but have not been tested in primary human T-cells. This is important because the 
behavior of pHSPs varies greatly between cell types and cellular states. In this study, we screen a library of 
pHSPs in primary T-cells and engineer gene circuits providing transient and sustained activation of gene 
expression in T-cells in response to brief thermal stimuli within the well-tolerated temperature range of 37–
42ºC22–24. Our circuits incorporate feed-forward amplification, positive feedback and recombinase-based 
state switches. We demonstrate the use of these circuits to control the secretion of a therapeutic cytokine, 
expression of a CAR, and killing of target tumor cells.
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RESULTS
Evaluating candidate pHSPs in primary T-cells. To enable thermal control of T-cell activity, we required a 
pHSP with robust switching behavior in primary human T-cells. Given the variability in pHSP responses 
between cell types25, we decided to systematically evaluate the activity of 13 different pHSPs in response to a 
1-hour incubation at 42ºC. This thermal stimulus was chosen based on its tolerability by most tissues24, and 
the convenience of relatively short treatment durations in potential clinical scenarios. Our panel of pHSPs 
included nine human, three mouse, and one C. elegans promoters. The human promoters included four 
naturally occurring sequences (HSPB, HSPB’2, HSP A/A, HSP A/B), two modifications of HSPB’2 
generated by varying the 5’ UTR (HSPB’1, HSPB’3), and three rational modifications of HSPB’2 
(SynHSPB’1, SynHSPB’2, SynHSPB’3) inspired by a previously developed sensor of cellular stress26. 
Truncating HSPB’2 and leaving 192 base pairs resulted in SynHSPB’1. To lower potential baseline activity, 
the AP-1 binding site in SynHSPB’1 was mutated leading to SynHSPB’2. Duplicating SynHSPB’2 four 
times to increase the number of heat shock elements (HSE) resulted in SynHSPB’3. The three mouse-
derived pHSPs were naturally occurring promoters. HSP16, derived from C. elegans, was first described in 
1986 and is rationally modified to form a minimal bidirectional promoter encompassing four HSE binding 
sites27. HSP16 excludes other transcription factor binding sites that typically exist in human promoters. We 
incorporated each pHSP into a standardized lentiviral construct in which the pHSP drives the expression of 
a green fluorescent protein (GFP), with a constitutively expressed blue fluorescent protein (BFP) serving as 
a marker of transduction (Fig. 1a). 
Once stimulated, all of the promoters displayed a uniform level of activation across the cell 
population allowing us to use mean fluorescence as a metric of fold induction (Fig. S1). Of our 13 
promoters, HSPB had the lowest baseline expression at 37ºC (Fig. 1b), an important property for 
minimizing activity in the absence of the thermal trigger. HSPB’1 showed the largest fold-change in gene 
expression, reflecting a combination of relatively low baseline expression and strong promoter activity when 
stimulated. Among the rationally engineered HSPB’2 variants, SYNHSPB’3 had a lower baseline than the 
natural promoter, albeit with lower maximum expression on activation. The rest of the human and mouse-
derived promoters exhibited high baseline activity, resulting in their elimination from further experiments. 
Finally, the C. elegans minimal promoter exhibited acceptable performance and was included in further 
testing to investigate whether its minimal composition would be advantageous for specific activation in 
response to temperature. Based on these factors, we chose HSPB, HSPB’1, SynHSPB’3 and HSP16 as our 
starting points for further circuit engineering. 
Thermal parameters for pHSP activation. After identifying four candidate pHSPs, we tested their response 
to a range of induction parameters. To search for temperatures that provide rapid induction with minimal 
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thermal burden to the cells, we incubated pHSP-transduced T-cells at temperatures ranging from 37ºC to 
44ºC for 1 hour. All four promoters exhibited a significant increase in activity starting at 42ºC (Fig. 2a). 
Increasing the induction temperature beyond this point resulted in a significant enhancement of 
transcriptional activity, but compromised cell viability (Fig. 2b). To optimize induction with minimal cell 
damage, we chose 42ºC for further experiments. We note that unlike the gradual increase in gene 
expression observed with the mammalian promoters above 42ºC, HSP16 exhibited a large jump between 
this temperature and 43ºC, which may make it useful in future circuit engineering applications. 
To reduce the effect of thermal exposure on cell viability, we tested a pulsatile heating scheme with 
a 50% duty cycle28. In this scheme, cells underwent repeated cycles of heating to 42ºC for a fixed duration 
and an equal amount of time at 37ºC, adding up to a total of one hour at 42ºC over a two-hour treatment 
period. We varied the stimulation period between one minute and continuous heating for 60 min. This 
experiment revealed a trade-off between promoter activity (Fig. 2c) and cell viability (Fig. 2d), with shorter 
pulses reducing the former while increasing the latter. For the purposes of T-cell therapy, in which cells can 
expand after activation, we decided that a 40% decrease in cell viability was a suitable trade-off for improved 
activation, therefore selecting a continuous heating paradigm. This paradigm also simplifies the application 
of heating during therapy. We also investigated continuous stimulation durations ranging from 15 to 120 
minutes. Shorter induction enhanced viability (Fig. 2e) at the expense of lower gene expression (Fig. 2f), 
with a one-hour stimulation providing a reasonable balance. While the optimal stimulation scheme would 
heavily depend on the promoter used, circuit design, targeted tissue, and therapeutic dose required, we 
chose a one-hour continuous stimulus at 42ºC as our heating paradigm for our subsequent experiments to 
maximize our chances of getting a meaningful response despite some damage to the cells. 
Genetic circuits for amplified and sustained thermal activation. On their own, pHSPs drove a relatively 
small amount of transient protein expression upon induction. To enable the use of pHSPs in T-cell therapy 
applications, it is useful to amplify the output of pHSP-driven circuits. This would enable cells to, for 
example, release a relatively large therapeutic bolus after a single thermal stimulus. To achieve this goal, we 
implemented a feed-forward amplification circuit in which the pHSP drives an rtTA transactivator, which 
produces stronger transcriptional activation tunable with doxycycline. In addition, LNGFR was 
constitutively expressed to identify virally transfected cells (Fig. 3a). Amplification circuits incorporating 
HSPB, HSPB’1, SynHSPB’3 and HSP16 all exhibited a substantial increase in their fold-induction, while 
only modestly elevating baseline expression. HSPB showed the best performance, suggesting that in the 
context of feed-forward amplification driving the maximum expression level, a promoter with lower leakage 
(Fig. 1b) is preferable. The expression of a constitutive transduction marker was similar across constructs 
(e.g. Fig. S2), indicating that infection levels did not affect their relative performance. To further tune the 
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performance of the HSPB amplifier circuit, we designed constructs with reduced translation of the GFP by 
varying the Kozak sequence or inserting a micro open reading frame upstream29 (Fig. 3b). These 
modifications enabled the tuning of both the baseline expression and the maximal activation level.
In some therapeutic scenarios, it is critical to prolong the therapeutic action of T-cells following a 
thermal induction treatment. This would eliminate the need to apply repeated stimuli to maintain treatment 
efficacy. To develop this capability, we established a positive feedback amplifier circuit by rearranging the 
elements of our feed-forward amplifier such that rtTA could drive its own expression in the presence of 
doxycycline (Fig. 3c). A similar design was previously tested in human cervical cancer HeLa cells30. The 
HSPB feedback circuit maintained its thermal induction level, and we were able to reduce baseline activity 
by tuning the Kozak sequence upstream of rtTA. In the current design, the output of the positive feedback 
circuit is lower than that of the feed-forward amplifier, as expected from the GFP payload being placed after 
an IRES element. While we envision that such “low but steady” activity is desirable in many applications, a 
“high and steady” mode could in principle be achieved by exchanging the IRES for a 2A element. The 
dynamic expression profiles of our direct, feed-forward, and feedback HSPB circuits are compared in Fig. 
3d, demonstrating prolonged expression with positive feedback. 
While the positive feedback circuit sustained expression for several days, this circuit can eventually 
turn off amid dilution or fluctuating expression of the transactivator. To establish a permanent thermal 
switch, we tested gene circuits in which we placed the expression of CRE recombinase under the control of 
candidate pHSPs (Fig. 3e). In these circuits, the pHSP-driven expression of CRE permanently toggles the 
circuit from expressing RFP to expressing anti-CD19 CAR by recombining the target vector. When tested 
in a Jurkat T-cell line, these circuits demonstrated robust activation and minimal leakage (Fig. 3f). However, 
when tested in primary T-cells, we observed significantly higher levels of background activation (Fig. 3f). 
This may arise from the fact that immune stimulation is used to maintain primary T-cells in culture and our 
finding, discussed below, that pHSPs show significant background activity in stimulated primary T-cells. 
Taken together, these results suggest that in primary T-cells, feed-forward and feed-back amplification 
provide robust methods for thermal control of gene expression, while pHSP-controlled CRE 
recombination may produce an unacceptable level of irreversibly accumulating background activation.
Temperature-activated cytokine release. To demonstrate the ability of our positive feedback circuit to 
sustain a therapeutically relevant function after thermal induction, we connected its output to the production 
of a cytokine. The local delivery of cytokines from engineered T-cells would be useful in cancer 
immunotherapy by allowing T-cells to secrete immune-stimulatory factors to remodel the tumor 
microenvironment and reduce immunosuppression. It would also be useful in treatments of autoimmune 
disease by allowing T-cells to secrete factors locally down-regulating the activity of endogenous immune 
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cells. As a model cytokine, we selected IL-21, which has potential utility in cancer immunotherapy due to its 
ability to stimulate NK cells and CD8+ T-cells31,32. We incorporated human IL-21 in place of GFP in our 
positive feedback circuit (Fig. 4a). Without thermal induction, primary T-cells transduced with this circuit 
produced minimal IL-21. Once stimulated, the cells rapidly secreted IL-21, reaching a near-maximal level 
by 12 hours, and sustained activity for at least 5 days (Fig. 4a). The dependence of continued circuit 
function on doxycycline provides an additional layer of control, allowing the termination of therapy 
production at a desired time by removing doxycycline. To demonstrate this capability, we removed 
doxycycline 24 hours after cell induction, resulting in the abrogation of cytokine production by day five. 
The ability to chemically terminate the activity of our circuit enhances its safety profile in potential 
therapeutic applications.
In some scenarios, it would be useful for cytokine release to be triggered from a T-cell constitutively 
expressing a CAR, allowing the cytokine to locally boost immune activation during CAR-directed killing. To 
test this possibility, we co-transduced primary T-cells with our positive IL-21 circuit and a constitutively 
expressed anti-CD19 CAR (Fig. 4b). In the absence of target Raji bait cells expressing CD19, IL-21 release 
was well-controlled by thermal induction (Fig. 4b). However, co-incubation with bait cells resulted in the 
activation of IL-21 release after 3 days in co-culture even in the absence of a thermal treatment (Fig. 4b). 
These results suggested that HSP activity may be driven by T-cell stimulation, as evidenced by IL-21 
release. However, since certain subsets of T-cells have been shown to release endogenous IL-21 when 
stimulated33, we set out to directly test the induction of pHSP upon T-cell stimulation using a non-cytokine 
output, as discussed below.
Dependence of pHSP-driven circuits on T-cell activation. To directly examine the possibility that pHSPs 
are turned on in response to CAR-driven T-cell activation, we tested the expression of pHSP-driven GFP in 
constitutively CAR-expressing T-cells (Fig. 5a) upon exposure to a thermal stimulus or bait cells. We found 
that both thermal stimulation and CAR engagement lead to pHSP-driven gene expression (Fig. 5b). This 
response occurred in cells expressing circuits based on HSPB, SynHSPB’3 and HSPmin promoters. 
Because SynHSPB’3 lacks the AP-1 site present in wild-type pHSPs such as HSPB, and HSPmin is 
composed of only HSE binding sites driving a minimal promoter, these results suggest that pHSP induction 
takes place via an HSF1-mediated mechanism. This unexpected finding suggests that activated T-cells 
experience cellular stress – for example due to rapid proliferation – potentially resulting in an increased 
number of mis-folded proteins, leading to HSP upregulation. This provides an important insight for the 
design of thermally inducible immunotherapies. 
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Auto-sustained thermally induced CAR expression and tumor cell killing.  Our finding that CAR 
engagement drives pHSP activity suggested that a simple, auto-sustained gene circuit could drive CAR-
mediated killing in response to the combination of a thermal stimulus and the presence of target cells. In 
particular, we hypothesized that placing CAR expression under the control of a pHSP (Fig. 6a) would result 
in T-cells with no initial CAR expression or activity, even in the presence of target cells. Upon thermal 
induction, CAR would become transiently expressed. If the CAR target is present in the vicinity of T-cells, 
these cells would become activated, driving sustained expression of additional CAR from the pHSP and 
target cell killing. 
As predicted, this pHSP-CAR circuit showed no baseline CAR expression in primary T-cells, but 
began to express CAR when thermally stimulated (Fig. 6a). CAR expression was greatly reduced after 24 
hours in the absence of target engagement (Fig. 6b). When cultured with CD19+ bait cells (Fig. 6c), 
thermally activated pHSP-CAR T-cells eliminated the bait cells after 9 days in co-culture (Fig. 6d, Fig. S3). 
This killing was as complete as with positive control T-cells carrying a constitutively expressed CAR driven 
by the EF1α promoter, albeit over a longer time span. This difference may be due to the maximum level of 
pHSP-driven CAR expression being lower than the level observed with a constitutive EF1α promoter (Fig. 
S4). When pHSP-CAR T-cells and bait cells were co-incubated without thermal stimulation, no apparent 
killing took place. While the initial thermal stimulus results in some cell death, T-cells maintain their 
proliferative capacity and rapidly make up for the initial loss in T-cells (Fig. S5). These results suggest that a 
thermal stimulus can kick-start a positive feedback loop of activation-driven expression of CAR from pHSP, 
leading to effective bait cell elimination. This activation paradigm could help with mitigating off-target 
toxicity since CAR expression will be abrogated once T-cells leave the tumor site. 
DISCUSSION
Our results demonstrate that engineered bioswitch circuits using pHSP can provide control of T-cell 
therapy with mild hyperthermia. While it has been previously shown that light-switchable proteins could 
also confer spatiotemporal control over T-cell activity34, light has poor penetration into tissues, limiting the 
utility of such tools. On the other hand, temperature can be elevated at arbitrary depth and with high spatial 
precision using non-invasive methods such as FUS or magnetic hyperthermia15–18. 
Our study showed that temperatures in the well-tolerated range of 37-42ºC35,36 can provide control 
over T-cell function, including the synthesis and release of a cytokine and the CAR-mediated killing of 
cancer cells in vitro, with minimal baseline activity. In future studies, this performance must be 
characterized and optimized in the in vivo setting. In particular, it will be useful to optimize the thermal 
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requirements of ultrasound activation. While thermal tissue damage is not a major concern in tumor 
therapy (where it can be synergistic), damage to healthy tissues in non-tumor applications could be 
detrimental35,36. It would also be desirable to shorten the FUS treatment duration to substantially less than 
the 1 hour heat pulse used in this study. Further promoter engineering, protein engineering and thermal 
pulse optimization could broaden the range of applications for this technology.
Despite their name, pHSPs can respond to a variety of stimuli such as heat, hypoxia, heavy metals, 
cytokines and cell division37,38. Therefore, the context in which these promoters are being used must be 
carefully considered. In this work, we capitalized on non-thermal pHSP induction by the T-cell receptor 
pathway to generate sustained killing circuits. In other contexts where the promiscuous responsiveness of 
pHSPs presents an un-exploitable hindrance, it may be desirable to develop thermal response mechanisms 
based on orthogonal molecular bioswitches22,23.
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METHODS
Plasmid Construction and Molecular Biology
All plasmids were designed using SnapGene (GSL Biotech) and assembled via reagents from New England 
Biolabs for KLD mutagenesis (E0554S) or Gibson Assembly (E2621L). After assembly, constructs were 
transformed into NEB Turbo (C2984I) and NEB Stable (C3040I) E. coli for growth and plasmid 
preparation. The CAR-CD19 gene containing the CD28 and CD3z signaling domain was a kind gift from 
the Laboratory of David Baltimore (Caltech). Integrated DNA Technologies synthesized other genes, the 
pHSP, and all PCR primers. Kozak used in figure 3B: CGG-ATG for 75% and ACCATGGGTTGAGCC-
ATG for 10%. The original kozak was ACC-ATG.
Cell Lines
Raji cells (CCL-86) were obtained from ATCC and cultured in RPMI 1640 media (Thermo Fisher 
Scientific) with 1x Penicillin/Streptomycin (Corning). 1000 ng/ml of doxycycline was used for induction of 
the Tet promoter. GFP+ Raji cells were constructed via viral infection of a GFP driven by the EF1a 
promoter. Lentivirus was prepared using a third-generation viral vector and helper plasmids (gifts of D. 
Baltimore). Virus was packaged in HEK293T cells grown in 10 cm dishes. After 3 days of transfection, viral 
particles were concentrated via Ultracentrifugation. Infection was performed by following the “RetroNectin” 
(T100B Takara Bio) reagent protocol. Experiments were performed at least two weeks after infection.
Primary T-cells
T-cells were isolated with the EasySep Human T-cell isolation Kit (STEMCELL Technologies 17951) from 
frozen human peripheral blood mononuclear cells obtained from healthy donors. T-cells were stimulated 
with CD3/CD28 Dynabeads (Thermo Fisher Scientific 11132D) at 1:1 cell:bead ratio for 1 day before viral 
transduction. Dynabeads were removed on day seven and the cells were allowed to rest until day fourteen 
before proceeding with experiments. This delay was designed to avoid any activation interference with HSP 
activity. T-cells were cultured in RPMI supplemented with 50 U/ml IL-2 (Miltenyi Biotech 130-097-744) 
and 1 ng/ml IL-15 (Miltenyi Biotech 130-095-762) every other day. T-cells were enriched by LNGFR 
magnetic bead based sorting (Miltenyi Biotech 130-091-330) when appropriate.  
Thermal Regulation Assay
Thermal stimulation of T-cells was performed in a Bio-Rad C1000 thermocycler. T-cells at 1-2 million/ml 
were supplemented with doxycycline, if needed, and mixed well before transferring 50 µl into a sterile PCR 
tube. The temperature and duration of stimulation was varied based on the experimental procedure. Upon 
completion of thermal stimulation, cells were moved back into a mammalian incubator and supplemented 
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1:1 with fresh media containing cytokines and in some cases doxycycline. Cells were typically incubated for 
24 hours unless stated otherwise before assaying with a flow cytometer (MACSQuant VYB). Dead cells 
were typically excluded via FSC/SSC gating for routine assays. In Figure 2, a LIVE/DEAD 
viability/cytotoxicity kit (Thermo Fisher L3224) was used for a more accurate quantification of cell state. 
Live cells were further gated via a transfection marker to isolate virally infected cells for further analysis. The 
change in mean fluorescence of the cell population was used to characterize the fold change of pHSP 
constructs. To account for cellular auto-fluorescence, the mean fluorescence signal from non-transduced T-
cells was collected in each experiment and subtracted from the mean fluorescence of experimental T-cells. 
Anti-HA antibodies (Miltenyi Biotech 130-120-722) were used to stain for CAR expression and V450 
Mouse Anti-human CD271 was used to stain LNGFR (BD biosciences 562123). IL-21 expression was 
measured using a human IL-21 DuoSet ELISA (R&D systems DY8879-05). 
T-cell Bait Assay
Raji and GFP+ Raji cells were used as bait cells for CAR-CD19 T-cells. Bait assays were initiated by mixing 
T-cells with bait cells at a 3:1 ratio. This ratio was established to avoid excessive bait cell growth before T-
cell engagement. To assess T-cell killing of bait cells GFP+ Raji were used and the count of GFP+ cells was 
tracked over time.
Data and code availability
Plasmids will be made available through Addgene upon publication. All other materials and data are 
available from the corresponding author upon reasonable request.
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Supplementary Material
Supplementary Figures S1-6; This includes (i) Thermally induced shift in gene expression, (ii) Expression of 
a transduction marker to control for variability in infection, (iii) Bait cell count for the HSP CAR killing 
experiment,  (iv) CAR expression from constitutive and induced constructs, (v) Assessing the proliferative 
capacity of stimulated T-cells, (vi) Assessing thermally induced CAR expression levels.
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FIGURE LEGENDS
Figure 1 | Evaluating candidate pHSPs in primary T-cells (a) Illustration of the screening strategy used to 
characterize the behaviour of pHSPs. The viral construct used to assay pHSPs is shown, along with the 
promoters tested. LTR, long terminal repeat. (b) Mean fluorescence intensity 24 hours after a 1-hour 
incubation at 37°C or 42ºC, as measured via flow cytometry. The fold change between 37°C and 42°C is 
listed above each sample. Where not seen, error bars (±SEM) are smaller than the symbol. N=3 biological 
replicates for each sample.
Figure 2 | Thermal parameters for pHSP activation in primary human T-cells. GFP expression from 
constructs driven by the HSPB, HSPB’1, SynHSPB’3 and HSP16F promoters (a, c, e) and T-cell viability 
(b, d, f) as a function of (a,b) induction temperature for a continuous 1 hour stimulus, (c,d) pulse duration 
of stimuli delivered with a 50% duty cycle alternating between 37ºC and 42ºC for a fixed thermal exposure 
of 1 hour, and (e,f) induction duration for continuous heating at 42ºC. Where not seen, error bars (±SEM) 
are smaller than the symbol. N=3 biological replicates for each sample.
Figure 3 | Genetic circuits for amplified and sustained thermal activation. (a) Diagram illustrating the 
thermally trigged feed-forward circuit (top). Fluorescence analysed 24 hours post a 1-hour induction at 37º 
or 42ºC for cells supplemented with doxycycline (bottom). (b) Diagram illustrating a feed-forward circuit 
driven by HSPB, <K> indicates varying kozak strength (top). Fluorescence analysed 24 hours post a 1-hour 
induction at 37º or 42ºC for cells supplemented with doxycycline (bottom). The HSPB data is the same as 
in panel (a), and is re-shown here to facilitate comparisons. (c) Diagram illustrating the thermally trigged 
positive feedback circuit (top). Fluorescence analysed 24 hours post a 1-hour induction at 37º or 42ºC for 
cells supplemented with doxycycline (bottom). (d) Normalized expression monitored over seven days after 
a 1-hour induction at 42ºC for direct HSPB-driven, feed-forward HSPB and positive-feedback HSPB 
circuits. Circuits have been modified to replace GFP with a destabilised version of the protein. (e) 
Illustration of the CRE based thermally triggered permanently stable switch designed to express CAR-CD19 
upon induction. (f) Cells were either incubated at 37ºC or thermally stimulated for 1 hour at 42ºC and 
analysed 24 hours later to determine the number of activated cells. Where not seen, error bars (±SEM) are 
smaller than the symbol. N=3 biological replicates for each sample.
Figure 4 | Temperature activated cytokine release. (a) Diagram illustrating the positive feedback circuit used 
to express IL-21 (top). Cumulative IL-21 release from 1-hour induction at 37º or 42ºC. In one sample, 
doxycycline was removed after 24 hours (bottom). (b) Illustration of the constructs used to assay the ability 
of CAR activity to trigger expression of IL-21 in the feedback pHSP circuit (top). Cells were either 
incubated at 37C or thermally stimulated for 1 hour at 42ºC with and without bait cells (bottom). Media was 
collected and frozen at each time point and all samples were analysed simultaneously at the end of 
collection. Cumulative IL-21 expression was quantified by using an IL-21 ELISA. Where not seen, error 
bars (±SEM) are smaller than the symbol. N=3 biological replicates for each sample.
Figure 5 | Dependence of pHSP-driven circuits on T-cell activation. (a) Illustration of the constructs used to 
assay the ability of CAR activity to trigger pHSP. (b) Cells were either incubated at 37ºC, thermally 
stimulated for 1 hour at 42ºC, or incubated with CD19+ bait cells. pHSP triggered activity was determined 
by quantifying GFP expression 24 hours after induction. Where not seen, error bars (±SEM) are smaller 
than the symbol. N=3 biological replicates for each sample.
Figure 6 | Auto-sustained thermally induced CAR expression and tumor cell killing. (a) Illustration of the 
viral construct used to assay pHSP (SynHSPB’3)-driven expression of CAR-CD19. Cells were either 
incubated at 37ºC or thermally stimulated for 1 hour at 42ºC and pHSP-triggered CAR-CD19 expression 
was quantified by surface staining of an HA tag appended to the CAR 12 hours after induction. N=3 
biological replicates. (b) CAR-CD19 expression 6, 12, and 24 hours after 1-hour induction with 37ºC or 
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42ºC. N=3 biological replicates. Negative values in 37ºC samples result from subtraction of signal acquired 
from wild-type T-cells. Raw data is provided in (Fig. S6). (c) Illustration of the viral construct and assay used 
to test the ability of pHSP-inducible CAR expression to conditionally kill bait cells. Cells were either 
incubated at 37ºC or thermally stimulated for 1 hour at 42ºC before being incubated with CD19+ bait cells. 
(d) Unmodified T-cells and T-cells constitutively expressing CAR-CD19 were used as a negative and 
positive control respectively. pHSP (SynHSPB’3) triggered killing activity was quantified by counting the % 
of bait cells alive compared to the negative control for a duration of 13 days. N= 3 biological replicates for 
two T-cell collections from different patients, total N=6. Where not seen, error bars (±SEM) are smaller 
than the symbol. 
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